

Dietary Composition and Weight Loss: Can We Individualize Dietary Prescriptions According to Insulin Sensitivity or Secretion Status?

Anastassios G. Pittas, MD, MSc, and Susan B. Roberts, PhD

There is considerable uncertainty over whether any one dietary pattern broadly facilitates weight loss or maintenance of weight loss, and current dietary guidelines recommend a spectrum of dietary composition for the general population. However, emerging evidence suggests that specific dietary compositions may work better for identifiable groups of overweight/obese individuals based on their individual metabolic status. In particular, characteristics of insulin dynamics, such as insulin sensitivity or insulin secretion status, may interact with diets that vary in macronutrient composition to influence the weight loss achieved with a hypocaloric diet.

Key words: dietary composition, insulin secretion, insulin sensitivity, weight loss

© 2006 International Life Sciences Institute

doi: 10.1301/nr.2006.oct.435–448

INTRODUCTION

The prevalence of overweight and obesity has increased dramatically in the United States and worldwide. In 2002, 69% of men and 62% of women in the United States were overweight or obese.¹ The cause of obesity is multifactorial, but lifestyle changes, in particular reduc-

ing energy intake, are the cornerstone of current approaches to weight loss and prevention of weight regain.^{2,3} However, weight loss (by any means) is recognized to be difficult to achieve and maintain, and there is considerable uncertainty over whether any one dietary pattern is broadly more effective than another.^{4–6} One promising area for improvement in the field of weight loss concerns whether individual-specific dietary recommendations may result in greater effectiveness of weight loss than group recommendations—in other words, whether different individuals respond better to different types of diets. In particular, there is animal and human evidence to suggest that insulin dynamics, such as insulin sensitivity and insulin secretion, play a role in body weight regulation and therefore these parameters may affect individual responses to hypocaloric diets. Furthermore, specific dietary factors that influence these parameters may theoretically interact with subject-specific characteristics of insulin dynamics to influence the effect of hypocaloric diets with varied macronutrient composition on weight loss and maintenance.

We performed a systematic review of observational and intervention human studies to address the following questions: 1) Are baseline insulin sensitivity and insulin secretion associated with future weight change, and might these parameters affect individual responses to hypocaloric diets? and 2) is there an interaction between either insulin sensitivity or insulin secretion and the macronutrient composition of hypocaloric diets that influences adherence to a weight loss program?

We conducted a review in MEDLINE of the English-language literature for observational and interventional (aiming at weight loss) human studies on the effect of baseline insulin sensitivity and insulin secretion on energy balance and future weight. Search terms included insulin sensitivity, insulin secretion, weight, dietary composition, and related terms. Additional publications were identified from citations from the recovered articles, review articles, and personal reference lists. We excluded letters, abstracts, and conference proceedings that were not published in full in peer-reviewed journals.⁷ We

Dr. Pittas is with the Division of Endocrinology, Diabetes and Metabolism, Tufts-New England Medical Center, Boston, Massachusetts; Dr. Roberts is with the Energy Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston.

Please address all correspondence to: Dr. Anastassios G. Pittas, Division of Endocrinology, Diabetes and Metabolism, Tufts-New England Medical Center, 750 Washington Street #268, Boston, MA 02111; Phone: 617-636-5694; Fax: 617-636-4719; E-mail: apittas@tufts-nemc.org.

This research was supported by National Institutes of Health grant K23-DK61506 (to A.G.P.) and US Department of Agriculture cooperative agreement No. 58-1950-4-401 (to S.B.R.).

also excluded studies in children because insulin dynamics are evolving during childhood, especially during puberty,^{8,9} and studies involving diabetic patients because they exhibit impaired and shifting insulin dynamics, insulin secretion in response to weight loss differs between diabetics and non-diabetics,¹⁰ and these individuals often try intentional weight loss (which may confound the relationship between insulin dynamics and weight in observational studies). Studies of less than 4 weeks follow-up or with fewer than eight participants were excluded. Qualitative synthesis of data was performed. We did not perform meta-analysis due to lack of uniformity in measuring predictor variables among the studies. Indices of insulin sensitivity and insulin secretion used in the reviewed studies are described in Table 1.

DIETARY MACRONUTRIENT COMPOSITION AND WEIGHT IN THE GENERAL POPULATION

Over the last decades, nutrition recommendations from national organizations have focused on prevention of chronic diseases such as cardiovascular disease and cancer, and there are no clear recommendations on macronutrient composition for weight control. As a result, a variety of dietary compositions have been proposed for

weight loss, and multiple popular diets with widely varied compositions are promoted.¹¹⁻¹³ Most concentrate on altering the relative contributions of fat and carbohydrate in the diet.

The role of dietary fat in the obesity epidemic has been a hotly debated topic for decades and remains unresolved. On theoretical grounds, dietary fat content can influence energy intake and body weight based on its higher energy density, higher palatability, and perhaps specific metabolic effects.¹⁴ The question of whether the consumption of a high-fat diet leads to weight gain and whether lower-fat diets can promote weight loss has been reviewed by our group previously.¹⁴⁻¹⁶

Studies that provided recommendations to lower fat intake have typically showed modest weight loss, while studies that provided the lower-fat diet showed greater weight loss, suggesting that adherence to a dietary regimen is of utmost importance. Based on these and other data, previous dietary guidelines have focused on lowering dietary fat,¹⁷ even though several groups have pointed out that the rising prevalence of obesity in the United States has occurred during a time when the percentage of dietary energy from fat has decreased, an association that clearly undermines the validity of the recommendations.¹⁸⁻²⁰

Table 1. Indices of Insulin Secretion and Insulin Sensitivity

Insulin Secretion		
Index	Procedure	Derivation of Index
INS ₃₀	75 g OGTT	Insulin value at 30 min after glucose load is given
OGTT-INS _{AUC-3hr}	75 g OGTT	Insulin AUC for the first 3 hours after glucose load is given
OGTT-INS _{D30}	75 g OGTT	(Insulin value at 30 min – insulin value at 0 min)/glucose value at 30 min
OGTT-CIR _{gp}	75 g OGTT	Corrected insulin release at the glucose peak
MTT-INS _{AUC-4hr}	Mixed Meal	Insulin AUC for the first 4 hours after a mixed meal is given
MTT-INS _{AUC-8hr}	Mixed Meal	Insulin AUC for the first 8 hours after two mixed meals are given
AIR _g	FSIVGTT ⁹⁴	Insulin AUC in the first 10 min after intravenous glucose administration
Disposition index	FSIVGTT	A measure of pancreatic function = Si × AIR _g
Insulin Sensitivity		
Index	Procedure	Derivation of Index
Fasting insulin	Serum	Fasting insulin
QUICKI	Fasting serum and plasma	= 1/[log(insulin, mU/L) + log(glucose, mg/dL)]
HOMA-IR	Fasting serum and plasma	=[(glucose, mmol/L) × (insulin, mU/L)]/22.5
OGTT-INS ₁₂₀	75 g OGTT	Insulin value at 120 min after glucose load is given
Insulin sensitivity	FSIVGTT	Insulin-mediated glucose disposal estimated by minimal model
M	Euglycemic hyperinsulinemic clamp	Amount of glucose necessary to maintain euglycemia during hyperinsulinemic conditions

AIR_g, acute insulin response to glucose; AUC, area-under-the-curve; CIR_{gp}, corrected insulin response at glucose peak; FSIVGTT, frequently sampled intravenous glucose tolerance test; HOMA-IR, homeostasis model assessment-insulin resistance; INS, insulin; MTT, meal tolerance test; OGTT, oral glucose tolerance test; QUICKI, quantitative insulin sensitivity check index.

In a recently published large trial that was initiated in 1993, postmenopausal women were randomized to a group receiving dietary advice to reduce ad libitum fat intake and replace it with vegetables, fruits, and grains or to a group receiving diet-related educational material.²¹ Women in the intervention group reported decreased fat and energy intake, had modest weight loss at 1 year, and maintained slightly lower weight (0.4 kg) than control women after an average of 7.5 years of follow-up. The results of this study are confounded by the intensive behavioral therapy that participants in the active low-fat group received, which may have led to additional behavioral changes favorable to weight loss. Therefore, from this and similar studies, it is difficult to differentiate the direct effects of the low-fat dietary composition on energy balance from the behavioral aspects of the intervention.

Diets high in fat and low in carbohydrate are frequently promoted for weight loss in popular books, and the scientific evidence has been reviewed.^{5,22} In the 94 highly heterogeneous and short-duration dietary interventions that have been conducted, participant weight loss was associated with decreased caloric intake and increased diet duration but not with reduced carbohydrate content. Since publication of the systematic reviews, there have been a number of larger and longer-duration trials of very-low-carbohydrate diets. All of these studies reported significantly more weight loss in the low-carbohydrate diet compared with the reduced-fat diet at 6 months,²³⁻²⁶ but the weight loss difference was attenuated in studies extended to 1 year.^{24,27}

In addition to changing the amount of carbohydrate, an alternative way of modifying the carbohydrate component (or glycemic load, $GL = \text{glycemic index [GI]} \times \text{carbohydrate amount}$) of the diet is to lower the glycemic index (GI) of ingested carbohydrates. However, there remains considerable controversy over the efficacy of low-GI diets for weight loss.²⁸ The GI is defined as the area under the glycemic response curve during a 2-hour period after consumption of 50 g of carbohydrate, and values are expressed relative to the effect of white bread or glucose.^{29,30} There have been several intervention trials (with a duration of 1 month or more) that have attempted to change the dietary GL moderately either by changing the amount or the GI of the ingested carbohydrate. These studies had conflicting results. Most found no change in weight between low- and high-GL diets,³¹⁻³⁶ but a few found more weight loss with the low-GL diet.^{37,38} Definitive conclusions are difficult to draw because these trials varied widely in methodology, but it appears that ad libitum, low-GL diets, including very-low-carbohydrate diets, cause significant weight loss initially, which is not, however, maintainable in the long term.^{24,27,37,38}

The studies summarized above have helped to pro-

long scientific uncertainty over whether low-carbohydrate or low-fat diets are the most effective for long-term weight control: overall, there appears to be little evidence for substantial quantitative differences in long-term group mean weight loss between low-fat and low-carbohydrate diets. However, targeting identifiable populations with specific macronutrient compositions based on physiological principles has barely been addressed to date, and may provide a new route to greater effectiveness in weight loss programs and prevention of weight gain.

INSULIN SENSIVITY AND WEIGHT

It is well established that obesity is associated with low insulin sensitivity or insulin resistance,³⁹ however, the temporal relationship between insulin resistance and obesity is not clear. In other words, it is not known whether insulin resistance precedes the development of obesity and plays a role in modulating future weight and response to hypocaloric diets.

Observational Studies of Insulin Sensitivity and Weight

In most observational studies, baseline insulin resistance measured in a variety of ways (Table 2) has been associated with less future weight gain in a variety of populations.^{10,40-47} However, the reverse association, that insulin resistance is associated with future weight gain, was seen in some studies,^{47,48} and no association was reported in other studies.^{45,49-52} From the available studies, it is difficult to draw definitive conclusions because most did not adjust for important contributors to energy balance and weight (e.g., physical activity, smoking, etc.) and were performed in widely varying populations with different genetic backgrounds, age, baseline weight, and degree of insulin resistance. For example, three studies were done in Pima Indians,^{10,40,43} who are considered to be genetically predisposed to obesity and insulin resistance, and tend to gain weight over time compared with age- and sex-matched non-Pima controls.⁵³ In summary, although our current understanding of the relationship between insulin sensitivity and weight is far from complete, it appears that insulin sensitivity, especially among young people and the less obese, is associated with future weight gain, while insulin resistance may provide a shield against future weight gain.

Insulin Sensitivity and Response to Hypocaloric Diets

A few intervention studies have examined whether insulin sensitivity modifies the effect of diets on weight

Table 2. Observational Studies Examining the Association Between Insulin Sensitivity Status and Future Weight Gain in Adults Without Diabetes

Study	Subject Characteristics			Follow-up (years)	Index of Insulin Sensitivity at Baseline (predictor variable)*	Association Between Index of Insulin Sensitivity and Outcome (weight)	Comments
	N	BMI (kg/m ²) mean or range	Age (yr), mean or range				
Swinburn 1991 ⁴⁰	193	34	25	3.5	Si	Si associated with weight gain; effect more pronounced in the less obese at baseline	Adjusted for age, sex, baseline weight, resting energy expenditure
Valdez 1994 ⁴¹	1493	24–28	25–64	8	FI	FI negatively associated with weight gain among obese	Adjusted for age, sex, baseline weight, ethnicity
Hoag 1995 ⁴²	789	26	53	4.3	FI	FI negatively associated with weight gain; effect stronger in obese	Adjusted for age, sex, baseline weight, ethnicity, smoking
Schwartz 1995 ⁴³	97	34	25	3	M	M associated with weight gain	Adjusted for age, sex, baseline weight, Si
Sigal 1997 ⁴⁴	107	25	33	16.7	Si, FI	Si associated with weight gain; FI not associated with weight gain; high AIR _g and Si had the most weight gain	Adjusted for age, baseline weight, Si
Folsom 1998 (CARDIA) ⁴⁵	3636	25	25	7	FI	Not associated with weight gain	Adjusted for age, sex, race, baseline weight, smoking
Folsom 1998 (ARIC) ⁴⁵	11,179	27	54	6	FI	FI negatively associated with weight gain	Adjusted for age, sex, race, baseline weight, smoking
Lazarus 1998 ⁴⁸	376	27	62	9	FI	FI associated with weight during first 3-year period; negatively associated with weight during second 3-year period	No adjustments
Zavarani 1998 ⁵⁰	647	25	40	14	OGTT-INS ₁₂₀	Not associated with weight gain	No adjustments; menopause confounding results
Gould 1999 ⁵⁹	767	25	53	4.4	FI, OGTT-INS ₁₂₀	FI, OGTT-INS ₁₂₀ not associated with weight gain	
Weyer 2000 ¹⁰	151	NR (mean weight 94 kg)	26	2.6	M	M associated with weight gain	
Wedick 2001 ⁴⁶	725	25	65	8	FI, HOMA-IR	FI/HOMA-IR associated with weight loss	Adjusted for age, baseline weight
Mayer-Davis 2003 ⁴⁹	554	27	30–69	5	FI, Si	FI, Si not associated with weight gain	Adjusted for age, sex, race, energy intake, alcohol, physical activity, smoking, baseline weight, demographics, behavior change
Mosca 2004 ⁵⁶	782	25	51	11	QUICKI	QUICKI with high fat consumption associated with weight gain	Adjusted for age, sex, race, alcohol, physical activity, baseline weight, energy intake
Howard 2004 ⁴⁷	3389	27	62	3	FI, HOMA-IR	FI, HOMA-IR associated with weight in lean women; negatively associated with weight in obese women	Adjusted for age, baseline BMI, physical activity, energy intake; latter two not associated with weight change
Silver 2006 ⁵²	N = 105	23	28	26	Si	Si not associated with weight gain	Adjusted for age, sex; weight self-reported

*See Table 1 for a description of indices of insulin sensitivity.

AIR_g, acute insulin response to glucose; BMI, body mass index; FI, fasting insulin; HOMA-IR, homeostasis model assessment-insulin resistance; INS₁₂₀, insulin level 2 hours after glucose loading; NR, not reported; OGTT, oral glucose tolerance test; QUICKI, quantitative insulin sensitivity check index; Si, insulin sensitivity.

loss. In a post hoc analysis of non-controlled, non-randomized weight loss trials in women, McLaughlin et al.⁵⁴ found no difference in weight loss in response to a hypocaloric diet when subjects were stratified by baseline insulin sensitivity. All subjects received a diet typical of the American diet (43% carbohydrate, 15% protein, 42% fat). In another weight loss study in women given a hypocaloric diet, those with central adiposity who had higher insulin resistance (and also higher insulin secretion) lost more weight compared with a group of woman with peripheral adiposity who had lower insulin resistance (and lower insulin secretion).⁵⁵

Insulin Sensitivity and Response to Hypocaloric Diets of Varying Macronutrient Composition

One observational study examined future weight in relation to the interaction between baseline insulin resistance and specific dietary composition.⁵⁶ In that study, after adjustment for a variety of factors including energy intake, those with high baseline insulin resistance showed more weight gain if they consumed a diet high in fat (>45% daily energy intake), an observation seen primarily in women.

In contrast, two intervention trials with a small number of subjects have reported that hypocaloric diets with lower GL may be more effective at promoting weight loss in individuals with higher insulin resistance at baseline.^{57,58} In a study by Baba et al.,⁵⁷ insulin-resistant (fasting insulin, 39 mU/L) obese men lost more weight when provided with a low-carbohydrate/high-protein diet vs. a high-carbohydrate/low-protein diet for 4 weeks. In the study by Cornier et al.,⁵⁸ a provided low-GL diet was more effective in women with more insulin resistance at baseline (based on higher fasting insulin), while a provided high-GL diet was more effective in those who were more insulin sensitive (based on lower fasting insulin). Self-reported energy intake and resting metabolic rate were the same in all four groups. Although the authors speculated that changes in other non-measured components of energy expenditure (feeding thermogenesis, greater physical activity, non-exercise activity thermogenesis, sleeping metabolic rate) may account for the differences, it is more likely that unreported differences in compliance were a contributing factor. Neither of these two studies adjusted for age, baseline weight, or other variables that may contribute to energy balance. Insulin resistance is usually associated with high insulin secretion; however, the interaction between insulin secretion status and diet was not examined in either of these studies.

In a recent trial by our laboratory, described in more detail below, baseline insulin resistance (by HOMA-IR) after adjustment for age, sex, and baseline weight, did

not predict weight loss in response to diets of varied GL.³⁵ However, although overweight, our participants were not particularly insulin resistant (mean fasting insulin 11.5 mU/L) and the study was small, so the absence of high insulin resistance at baseline may have not allowed us to detect an interaction between insulin resistance and dietary composition on weight loss. Further studies in this area are clearly needed.

INSULIN SECRETION AND WEIGHT

Only a few studies have examined the relationship between insulin secretion and weight (Table 3). In an observational study by Sigal et al.⁴⁴ of young adult offspring of two parents with type 2 diabetes, acute (first-phase) post-challenge hyperinsulinemia (as measured by acute insulin response to glucose, AIRg) was a predictor of future weight gain independent of age or baseline weight. The authors attempted to distinguish the effect of insulin sensitivity from that of insulin secretion (given their close correlation) by stratifying the cohort into four groups with respect to median values for insulin sensitivity and insulin secretion. The group with both high baseline AIRg and insulin sensitivity exhibited the most weight gain over time. The authors speculated that insulin sensitivity may play a permissive role for the effect of insulin hypersecretion on weight gain.⁴⁴ In other words, in this model, insulin hypersecretion would lead to weight gain only if a certain threshold of insulin sensitivity is reached. The combination of high insulin sensitivity and secretion is not common but may be important in relation to certain macronutrient compositions, as discussed later.

Two other studies found no association between AIRg and future weight.^{49, 52} One study of young individuals followed participants for 26 years, with weight being self-reported and no adjustment made for important confounders (physical activity, dietary composition, etc.).⁵² The other study in older individuals adjusted for a variety of potentially confounding variables including energy intake.⁴⁹ Since increased energy intake is one mechanism by which insulin hypersecretion may influence future weight, as discussed below, adjusting for energy intake may explain the null association in this study.

Two studies in Pima Indians provide conflicting results. The earlier study⁴³ found that elevated baseline insulin secretion (after either an oral or intravenous glucose challenge) was inversely correlated with weight gain 3 years later, after adjusting for insulin sensitivity (which was positively associated with future weight gain). However, in a more recent, larger study in Pima Indians,¹⁰ no association was seen between stimulated insulin release (as measured by AIRg) and future weight.

Table 3. Observational Studies Examining the Association Between Insulin Secretion Status and Future Weight Gain in Adults Without Diabetes

Study	Subject Characteristics			Follow-up (years)	Index of Insulin Secretion at Baseline (predictor variable)*	Association Between Index of Insulin Sensitivity and Outcome (weight)	Comments	
	N	BMI (kg/m ²) mean or range	Age (y), mean or range					
Schwartz 1995 ⁴³	97	34	25	3	MTT-INS _{AUC-4hr} OGTT-INS _{AUC-3hr} AIR _g	All measures negatively associated with weight gain	Adjusted for age, sex, baseline weight, Si	
Sigal 1997 ⁴⁴	107	25	33	16.7	M/F M/F Offspring of type 2 diabetes patients	AIR _g associated with weight gain	Adjusted for age, baseline weight, Si	
Gould 1999 ⁵⁹	767	25	53	4.4	M/F Caucasian	OGTT-INS _{D30} not associated with weight gain in males; OGTT-INS _{D30} negatively associated with weight gain in females > 50y	No adjustments; menopause confounding results	
Weyer 2000 ¹⁰	151	NR (mean weight 94 kg)	26	2.6	M/F Pima Indian	AIR _g	AIR _g not associated with weight gain	
Mayer-Davis 2003 ⁴⁹	554	27	30–69	5	M/F	AIR _g , DI	AIR _g , DI not associated with weight gain	Adjusted for age, sex, race, energy intake, alcohol, physical activity, smoking, base weight, demographics, behavior change
Silver 2006 ⁵²	105	23	28	26	M/F	AIR _g	AIR _g not associated with weight gain	Adjusted for age, sex; weight was self-reported

*See Table 1 for a description of the indices of insulin secretion.

AIR_g, acute insulin response to glucose; AUC, area under the curve; BMI, body mass index; DI, disposition index; INS, insulin; MTT, meal tolerance test; NR, not reported; OGTT, oral glucose tolerance test.

Gould et al.⁵⁹ also found a negative association between baseline insulin secretion (based on an oral glucose tolerance test) and future weight gain in Caucasians women over age 50 but not in younger women or men. The changes in body composition that occur during menopause and the lack of adjustment for hormone therapy and other variables may have confounded the results of this study.

Insulin Secretion and Response to Hypocaloric Diets

There has been very limited exploration of the effects of insulin secretion on weight loss response to hypocaloric diets in intervention trials (Table 4). Initial evidence for an important role of insulin secretion in energy balance and weight loss comes from pharmacologic studies in which insulin secretion was suppressed with pharmacologic agents and weight loss response assessed. In one such study, obese participants were all given a hypocaloric diet and then randomized to either placebo or diazoxide, a K⁺[ATP] channel agonist that decreases insulin secretion and is used in the medical management of insulinomas.⁶⁰ Compared with the placebo group, the diazoxide group lost more weight (4.6 vs. 9.5 kg, respectively) while on the hypocaloric diet, supporting an important role for insulin secretion in modifying weight loss in response to caloric restriction.

In another pharmacologic study in obese individuals, insulin secretion was suppressed by octreotide-LAR, a somatostatin analog used in various endocrine hypersecretory conditions, without a concomitant lifestyle intervention.⁶¹ For the entire cohort, significant insulin suppression was achieved with accompanied weight loss and decreased self-reported carbohydrate craving. In a post hoc analysis, participants who lost the most weight exhibited the highest suppression in pancreatic beta-cell activity and the highest reduction in carbohydrate cravings and intake. During the baseline oral glucose tolerance test, this group exhibited a rapid increase and a high peak in insulin level, followed by a rapid decline, suggesting that first-phase insulin hypersecretion (first 30 min) may be particularly important. Although insulin-independent effects of octreotide cannot be ruled out (such as effects on incretins, gastric motility, etc.), the results of this pharmacologic study, which was done without an accompanied caloric restriction prescription, provide further support for an important role of insulin hypersecretion in the genesis of obesity.

There are other types of data that are broadly consistent with the hypothesis that insulin secretion status influences weight loss. In a study of women given a hypocaloric diet for weight loss, those with central adiposity who also had higher insulin secretion and higher

insulin resistance lost more weight compared with a group of women with peripheral adiposity who had lower insulin secretion and lower insulin resistance.⁵⁵ In contrast, in a post hoc analysis of a non-randomized, non-controlled, short-term intervention study in women given a hypocaloric diet (43% carbohydrate, 15% protein, and 42% fat), the baseline integrated insulin response (as measured by the meal tolerance test, MTT-INS_{AUC-8hr}) to two consecutive meal challenges did not predict weight loss in response to the diet.⁵⁴ However, this study was small (N = 20) and no adjustments were made for other important factors such as menopausal status.

In summary, the contribution of insulin secretion to future weight and response to hypocaloric diets, including those that vary in macronutrient composition, is controversial and its effects are difficult to isolate from insulin resistance. However, baseline insulin secretion status may be important with regard to dietary macronutrient composition, as discussed below.

INSULIN SECRETION AND RESPONSE TO HYPOCALORIC DIETS OF VARYING MACRONUTRIENT COMPOSITION

Although the topic of whether insulin secretion affects the ability of overweight individuals to lose weight in response to a non-specific hypocaloric diet is a new and important area for study, the influence of insulin hypersecretion in modulating weight loss may be particularly important for specific dietary compositions, in particular diets that differ in GL.^{29,62} This hypothesis is suggested by animal studies^{63,64} and results from a recent human study in our laboratory.³⁵

As described above, weight loss studies with varied macronutrient composition, including those using the concept of the dietary GL, have shown conflicting results for heterogeneous groups of individuals.^{31,32,34,37,65-67} As a result, currently there is no general consensus about the relative benefits or disadvantages of these types of diets for weight loss in the general population. However, our new findings³⁵ may provide an explanation for the conflicting results seen in human studies of weight loss utilizing a variety of macronutrient compositions, since none of these studies examined the effects of the different diets stratified by baseline insulin secretion or other measures of metabolic status.

We recently completed a small, randomized, double-blind, controlled feeding trial in healthy overweight adults to examine the weight loss effects of two hypocaloric diets differing in GL. Participants were randomized for 24 weeks to a provided diet with either a high GL (60% carbohydrate, 20% protein, 20% fat, fiber 15 g/1000 kcal, mean estimated daily GI of 86 and GL of 116 g/1000 kcals) or a low GL (40% carbohydrate, 30%

Table 4. Weight Loss Intervention Studies That Have Examined the Interaction between Glucose-Insulin Dynamics Status and Weight in Adults Without Diabetes

Study	Subject Characteristics			Type of Study	Duration (weeks)	Predictor of Metabolic Profile*	Study Arms and Intervention		Outcome: Weight (kg)	Comments
	BMI (kg/m ²) mean or range	Age (y) mean or range	Other							
Casimirri 1998 ⁵⁵	34	41	F	No control	16	OGTT, FI	1. Higher FI and OGTT-INS, <i>n</i> = 10 2. Lower FI and OGTT-INS, <i>n</i> = 10 All subjects received hypocaloric diet (20% protein, 30% fat, 50% carbohydrate)	-13 -8.6	No changes in energy intake!	
Alemzadeh 1998 ⁶⁰	41	30	M/F	RCT	8	AIR _g	1. Diazoxide (lower AIR _g), <i>n</i> = 12 2. Placebo (higher AIR _g), <i>n</i> = 12 All subjects received hypocaloric diet (Optifast)	-9.5 -4.6	No changes in REE; no changes in carbohydrate/fat oxidation; no adjustments	
Baba 1999 ⁵⁷	35	NR	M FI > 25 mU/L	RCT	4	FI	1. LC/HP, <i>n</i> = 7 2. HC/LP, <i>n</i> = 6 Hypocaloric diet (80% REE) provided to all subjects	-8.3 -6.0	No comparison group with lower FI (higher insulin sensitivity); no adjustments	
McLaughlin 1999 ⁵⁴	31	42	F	No control post hoc	8	MTT-INS _{AUC-8hr} M	1. IR and high INS _{AUC-8hr} , <i>n</i> = 10 2. IS and low INS _{AUC-8hr} , <i>n</i> = 10 Hypocaloric diet (liquid formula) provided to all subjects	-9.3 -9.1	Only diet successes were followed; no adjustments	
Velasquez-Meyer 2003 ⁶¹	44	39	M/F	No control post hoc	24	OGTT-CIRgp	All subjects received Octreotide-LAR monthly, <i>n</i> = 44 all subjects	-3.6	Post-hoc: Those with more weight loss had higher insulin suppression and less carbohydrate craving and intake; no lifestyle intervention prescribed; high responders had higher BMI at baseline; no adjustments	
Cormier 2005 ⁵⁸	30-35	23-53	F	RCT	16	FI	1. IS (FI < 10) HC/LF diet, <i>n</i> = 6 2. IS (FI < 10) LC/HF diet, <i>n</i> = 6 3. IR (FI > 15) HC/LF diet, <i>n</i> = 4 4. IR (FI > 15) LC/HF diet, <i>n</i> = 5 All subjects provided with hypocaloric diet (400 kcal deficit)	-13.5 -6.8 -8.5 -13.4	Self-reported energy intake; RMR did not change among 4 groups; no adjustments	
Pittas 2005 ⁵⁵			M/F	RCT	24	INS ₃₀ , HOMA-IR	1. Low INS ₃₀ HG diet, <i>n</i> = 8 2. Low INS ₃₀ LG diet, <i>n</i> = 8 3. High INS ₃₀ HG diet, <i>n</i> = 8 4. High INS ₃₀ LG diet, <i>n</i> = 8 All subjects provided with hypocaloric HG or LG diet (70% of TEE)	-8 -5.3 -6.2 -10	No adjustments for physical activity	

*See Table 1 for a description of indices of insulin sensitivity or insulin secretion.

AIR_g, BMI, body mass index; CIR_{gp}, corrected insulin response at glucose peak; FI, fasting insulin; LC, low carbohydrate; HC, high carbohydrate; HF, high fat; HG, high glycemic load; HOMA-IR, homeostasis model assessment-insulin resistance; INS₃₀, insulin level 30 minutes after glucose loading; IR, insulin-resistant; IS, insulin-sensitive; LF, low fat; LG, low glycemic load; OGTT, oral glucose tolerance test; RCT, randomized placebo controlled trial; RMR, resting metabolic rate.

protein, 30% fat, fiber 15 g/1000 kcal, mean estimated daily GI of 53 and GL of 45 g/1000 kcals) at 30% calorie restriction compared with baseline individual energy needs. In a post hoc multivariate prediction analysis, we examined whether the weight loss effects of the two diets varied according to baseline insulin secretion and insulin resistance. Simple indices of insulin secretion, insulin level 30 minutes after glucose loading (INS₃₀) and homeostasis model assessment-insulin resistance (HOMA-IR) were examined for their ability to predict change in weight from baseline to 6 months. A total of 32 (25 women and 7 men) out of 34 enrolled participants completed the 6-month intervention. At baseline, mean fasting glucose was 84 mg/dL and insulin was 11.5 mU/L. Both groups achieved statistically significant ($P < 0.001$) weight loss compared with their baseline weight. Adjusted for baseline weight and other baseline variables, weight loss was equivalent in the two groups both at 3 and 6 months.

In multivariate prediction models, there was no diet \times HOMA-IR interaction, but there was a diet \times INS₃₀ interaction ($P = 0.02$). Therefore, we examined the weight data stratified into two groups separated by the median INS₃₀ value (Figure 1). Participants with relatively high baseline INS₃₀ lost more weight if randomized to the low-GL diet compared with the high-GL diet ($P < 0.05$). In participants with relatively low baseline INS₃₀, those in the high-GL diet group lost more weight than those in the low-GL diet group, but the difference was not statistically significant. We concluded that in healthy overweight individuals examined without

respect to their baseline metabolic profile, calorie-restricted diets of varying GL result in equivalent weight loss. However, based on the multivariate analysis, a calorie-restricted diet low in GL led to more weight loss in those who had relatively higher stimulated insulin secretion at baseline.³⁵

Our participants were not particularly insulin resistant, and therefore the lack of relative insulin resistance in those with high insulin release may have predisposed this group of individuals to weight gain. This was suggested by the data from Sigal et al.,⁴⁴ and was reversed by a low-GL diet. However, because of our small number of participants, we were unable to test the hypothesis that insulin sensitivity plays a permissive role, so further research in this area is needed.

MECHANISMS LINKING INSULIN DYNAMICS, WEIGHT, AND DIETARY COMPOSITION

Insulin is a primary hormonal mediator of energy balance and storage, with multiple effects on the periphery (muscle, liver, and adipose tissue) and central nervous system (CNS). Therefore, changes in the insulin axes have been proposed as having an important role in the dysregulation of energy balance leading to obesity, although the exact mechanisms are far from clear.

In the periphery, insulin secreted after a meal acts as an anabolic hormone, promoting fuel storage and favoring weight gain. From an evolutionary point of view, insulin hypersecretion in response to a meal may have conferred a survival advantage by increasing the efficiency of energy storage in adipose tissue (the “thrifty genotype hypothesis”).⁶⁸ In our society, where food is readily available, this characteristic may lead to excessive weight gain and fat accumulation. This hypothesis is in accord with studies that found an association between insulin secretion and weight gain,^{44,69,70} although not all studies have found this association.^{10,49,52}

Evidence of an association between insulin hypersecretion and weight gain comes from medical conditions such as insulinomas, which are pancreatic beta cell tumors that secrete excessive insulin independent of blood glucose concentration. Patients with insulinomas report hyperphagia and significant weight gain.⁷¹ Additional evidence comes from iatrogenic insulin hypersecretion in patients with type 2 diabetes treated with insulin secretagogues, which leads to weight gain and fat accumulation.^{72,73}

A mechanism that can explain the association between insulin hypersecretion, especially post-challenge hyperinsulinemia, and future weight gain is the development of hypoglycemia (absolute or relative) in the post-absorptive period, which produces a pattern of increased hunger, frequent snacking, and increased energy in-




Figure 1. Mean (SEM) weight change during a 6-month feeding study of a high- (HG) vs. a low- (LG) glycemic load diet in overweight adults stratified by baseline insulin secretion based on serum insulin at 30 minutes after a 75 g oral glucose tolerance test. Low INS-30, <473 pmol/L (66 mU/L); High INS-30, >473 pmol/L. P values are adjusted for baseline weight. * $P < 0.005$ for within-group change in weight from baseline. From Pittas et al., 2005³⁵; used with permission.

take.⁷⁴⁻⁷⁸ This is thought to be the primary cause of weight gain in medical or iatrogenic conditions associated with insulin hypersecretion,⁷¹⁻⁷³ although variations in glycemia within the normal physiologic range are probably only one of several factors in overall energy regulation.^{76,79} However, there is also evidence to suggest that relative hypoglycemia contributes to increased energy intake in healthy, non-obese individuals.⁷⁶

There are also animal⁸⁰ and human⁸¹ data suggesting that acute hypersecretion of insulin may increase hunger without the intermediate step of hypoglycemia. In a rat model of obesity, lesions in the ventromedial hypothalamus cause excessive insulin secretion, hyperphagia, and weight gain, all of which are blocked by pancreatic vagotomy.⁸²⁻⁸⁴ In healthy human subjects, short-term infusion of insulin induces hunger, carbohydrate cravings, and hyperphagia, which are unrelated to changes in blood glucose concentration.^{85 81}

Insulin is also known to have a centrally mediated effect on food intake and body weight regulation, with higher insulin levels in the CNS associated with reduced appetite and caloric intake, causing weight loss.⁸⁶⁻⁸⁹ In this case, the central (catabolic) effects of insulin apparently attempt to counteract its peripheral (anabolic) effects that would favor weight gain. Which specific effects of insulin predominate, the central or peripheral, is not clear. In observational studies, younger age and lower weight (both associated with increased insulin sensitivity) are associated with weight gain, while older age and higher weight (both associated with insulin resistance) are associated with attenuation of weight gain or weight loss.^{10,41,44,46,47,51,69} It is possible that the peripheral effects of insulin may be more pronounced when the individual is leaner and younger, when energy storage is needed, while the central effects of insulin may be more pronounced when insulin resistance and the accompanied hyperinsulinemia develop in association with aging and obesity.

The association of insulin resistance with less future weight gain seen in certain studies^{10,40-47} may therefore be explained by a negative feedback loop in which as weight increases, insulin resistance rises, which leads to persistently elevated circulating insulin levels, which in turn slows down the rate of weight gain via insulin's central effects. Increased circulating insulin levels during insulin resistance signal satiety to the CNS, thereby limiting food intake and decreasing insulin levels during weight loss, thus reducing satiety and promoting weight gain. The development of insulin resistance may also have peripheral effects that lead to decreased carbohydrate oxidation, which would, in turn, increase fat oxidation limiting fat storage and leading to weight loss or attenuation of weight gain.^{40,88} Therefore, the development of insulin resistance and consequent hyperinsulin-

emia can be seen as physiologic adaptations to obesity that attenuate further weight gain via the effects of insulin in the CNS and periphery to maintain stable weight.^{88,90,91}

Insulin Sensitivity vs. Insulin Secretion

The inconsistency seen among studies of insulin dynamics and future weight may, at least in part, be due to the difficulty in isolating insulin sensitivity from insulin secretion, as these two measures are closely and inversely correlated.^{40,43} Namely, it is difficult to determine whether the hyperinsulinemia (fasting or postprandial) seen in obese individuals is due to excessive and inappropriate insulin secretion or if it constitutes an appropriate (compensatory) response to increased insulin resistance necessary for maintaining euglycemia. Indeed, a positive association between insulin sensitivity and future weight gain was seen in Pima Indians, but the association was attenuated after adjusting for baseline insulin secretion (which is low in insulin-sensitive individuals).⁴³

Fasting vs. Post-Prandial Insulin Secretion

A distinction should also be made between prevailing hyperinsulinemia (measured during fasting) and post-challenge insulin secretion. Insulin hypersecretion in response to a meal, which is short-lived, may have a predominant peripheral anabolic effect that would favor weight gain. On the other hand, chronic hyperinsulinemia, which reflects insulin resistance, may have a predominant effect on the brain to decrease appetite and lower food intake,^{87,88} which may counteract the peripheral anabolic effects of the acute burst of insulin secretion that would favor weight gain. In other words, the acute effect of insulin hypersecretion may be different from the chronic persistent hyperinsulinemia that develops in obese individuals and in genetically predisposed individuals such as Pima Indians.^{40,43} There is also evidence that first-phase insulin secretion may be more important than second-phase or persistent hyperinsulinemia.^{44,61}

Interaction Between Insulin Secretion and Insulin Sensitivity

Insulin sensitivity and secretion may also interact with each other to influence weight, as shown in the study by Sigal et al.,⁴⁴ in which those with high insulin secretion and insulin sensitivity gained the most weight. The net effect on weight depends on whether insulin secretion is an appropriate response to insulin resistance. In that case, the hyperinsulinemia may serve as an

adaptation to weight maintenance. But if insulin hypersecretion is excessive in relation to insulin resistance, then insulin hypersecretion may promote weight gain via its actions as an anabolic hormone, promoting lipid and carbohydrate storage in peripheral tissues. Therefore, acute hyperinsulinemic response may be an early determinant of obesity but only in the context of normal or increased insulin sensitivity (i.e., inappropriate for the degree of insulin sensitivity). This observation may also explain the result seen in Pima Indians, a population with high insulin resistance that may not be characteristic of the population at large, where insulin release was negatively associated with weight gain.⁴³

While the combination of increased insulin secretion and sensitivity is probably uncommon, this combination may be more prevalent in individuals who consume a high-GL diet. If an individual is genetically insulin sensitive and predisposed to insulin hypersecretion, then high-GL diets are likely to promote insulin secretion, leading to fuel storage via insulin's anabolic action.

INSULIN DYNAMICS AND HIGH-GL DIETS

Although baseline insulin dynamics may play a subtle role in energy regulation and the pathogenesis of obesity, the insulin axis may become quantitatively more important in the setting of varied macronutrient dietary composition, especially by diets that vary in GL.

Hypersecretion of insulin in response to a high-GL diet has been proposed as one mechanism for the weight gain seen in rats fed a high-GI diet.⁶³ A high-GL diet appears to elicit short-term metabolic responses, including an increase in post-prandial insulin concentration. Post-challenge insulin secretion, which is a significant contributor to high circulating insulin levels in obese persons, favors fatty acid uptake, inhibits lipolysis, and favors energy storage, all mechanisms leading to weight gain. Therefore, it is possible that recurrent insulin hypersecretion induced by chronic exposure to high-GL diets may play a role in the pathogenesis of obesity in susceptible individuals (those with high insulin secretion).

In addition to post-prandial relative hyperinsulinemia and post-absorptive relative hypoglycemia, high-GL diets may also lead to other post-prandial metabolic changes, including an increase in counterregulatory hormones (cortisol, glucagon, growth hormone), which may further contribute to hunger and increased energy intake in the post-absorptive period.⁹² All of these mechanisms may be exacerbated in individuals with high insulin secretory capacity at baseline, which could make them more susceptible to weight gain upon exposure to a high-GL diet. If this hypothesis holds true, then a low-GL diet in predisposed individuals may prove

beneficial by decreasing insulin excursion and breaking the vicious cycle. This is in accord with both animal data⁶⁴ and the results of our study,³⁵ as we found that healthy overweight adults with relatively high rates of insulin secretion during a standard oral glucose tolerance test lost significantly more weight when assigned to a low-GL diet than a high-GL diet.

Observational vs. Intervention Studies

It is important to note that, in relation to how metabolic profile influences weight, there are differences between short vs. long-term follow-up periods and between active weight loss vs. maintenance of weight loss. The baseline insulin dynamics may influence short-term future weight and weight loss during the active phase of lifestyle changes. However, long-term energy balance and weight maintenance may be further influenced by the change in insulin dynamics, other metabolic variables, and of course lifestyle factors. Weight loss leads to improvements in insulin sensitivity, which in turn affects insulin release, and these changes may be permissive or resist further weight loss. Yost et al.⁹³ reported that improvement in insulin sensitivity with weight loss predicts future weight gain during the maintenance period. This also needs to be taken into consideration in future studies. For example, re-characterization of the metabolic profile at the beginning of the weight maintenance phase may be needed to examine how the changed metabolic profile influences weight maintenance. One may speculate that, after attaining weight loss with a specific macronutrient composition, to achieve weight maintenance, dietary composition may need to change over time to accommodate the changing metabolic profile.

CONCLUSION

Current dietary guidelines recommend a spectrum of dietary composition for the general population, but emerging evidence suggests that specific dietary compositions may work better for identifiable groups of overweight/obese individuals based on their insulin dynamics. In particular, subject-specific insulin secretion status and perhaps insulin sensitivity may interact with diets that vary in glycemic load to influence the weight loss response to a hypocaloric diet. Appropriately powered clinical studies and, ultimately, randomized controlled trials of dietary composition and weight loss in participants with varied insulin sensitivity and insulin secretion are needed to further clarify the role of individualizing dietary prescriptions in long-term weight control.

REFERENCES

1. Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999–2002. *JAMA*. 2004;291(23):2847–2850.
2. Ross R, Janssen I, Tremblay A. Obesity reduction through lifestyle modification. *Can J Appl Physiol*. 2000;25(1):1–18.
3. Wing RR, Phelan S. Long-term weight loss maintenance. *Am J Clin Nutr*. 2005;82(suppl 1):222S–225S.
4. Freedman MR, King J, Kennedy E. Popular diets: a scientific review. *Obes Res*. 2001;9(suppl 1):1S–40S.
5. Bravata DM, Sanders L, Huang J, Krumholz HM, Olkin I, Gardner CD. Efficacy and safety of low-carbohydrate diets: a systematic review. *JAMA*. 2003;289(14):1837–1850.
6. Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. *JAMA*. 2005;293(1):43–53.
7. Toma M, McAlister FA, Bialy L, Adams D, Vandermeer B, Armstrong PW. Transition from meeting abstract to full-length journal article for randomized controlled trials. *JAMA*. 2006;295(11):1281–1287.
8. Polonsky KS, Given BD, Hirsch L, et al. Quantitative study of insulin secretion and clearance in normal and obese subjects. *J Clin Invest*. 1988;81(2):435–441.
9. Bloch CA, Clemons P, Sperling MA. Puberty decreases insulin sensitivity. *J Pediatr*. 1987;110(3):481–487.
10. Weyer C, Hanson K, Bogardus C, Pratley RE. Long-term changes in insulin action and insulin secretion associated with gain, loss, regain and maintenance of body weight. *Diabetologia*. 2000;43(1):36–46.
11. Atkins R. *Dr. Atkins' New Diet Revolution*. New York: Avon Books; 1998.
12. Sears B. *The Zone: A Dietary Road Map*. New York: HarperCollins Publishers; 1995.
13. Ornish D. *Everyday Cooking With Dean Ornish*. New York: HarperCollins Publishers; 1997.
14. Roberts SB, McCrory MA, Saltzman E. The influence of dietary composition on energy intake and body weight. *J Am Coll Nutr*. 2002;21(2):140S–145S.
15. Roberts SB, Pi-Sunyer FX, Dreher M, et al. Physiology of fat replacement and fat reduction: effects of dietary fat and fat substitutes on energy regulation. *Nutr Rev*. 1998;56(5 part 2):S29–S41.
16. Yao M, Roberts SB. Dietary energy density and weight regulation. *Nutr Rev*. 2001;59(8 part 1):247–258.
17. US Department of Health and Human Services, US Department of Agriculture. *Dietary Guidelines for Americans 2000*. Available at: <http://www.health.gov/dietaryguidelines/dgac/>. Accessed August 30, 2006.
18. Ludwig DS. The glycemic index: physiological mechanisms relating to obesity, diabetes, and cardiovascular disease. *JAMA*. 2002;287(18):2414–2423.
19. Willett WC, Leibel RL. Dietary fat is not a major determinant of body fat. *Am J Med*. 2002;113(suppl 9B):47S–59S.
20. Willett WC. Dietary fat plays a major role in obesity: no. *Obes Rev*. 2002;3(2):59–68.
21. Howard BV, Manson JE, Stefanick ML, et al. Low-fat dietary pattern and weight change over 7 years: the Women's Health Initiative Dietary Modification Trial. *JAMA*. 2006;295(1):39–49.
22. Eisenstein J, Roberts SB, Dallal G, Saltzman E. High-protein weight-loss diets: are they safe and do they work? A review of the experimental and epidemiologic data. *Nutr Rev*. 2002;60(7 part 1):189–200.
23. Brehm BJ, Seeley RJ, Daniels SR, D'Alessio DA. A randomized trial comparing a very low carbohydrate diet and a calorie-restricted low fat diet on body weight and cardiovascular risk factors in healthy women. *J Clin Endocrinol Metab*. 2003;88(4):1617–1623.
24. Foster GD, Wyatt HR, Hill JO, et al. A randomized trial of a low-carbohydrate diet for obesity. *N Engl J Med*. 2003;348(21):2082–2090.
25. Samaha FF, Iqbal N, Seshadri P, et al. A low-carbohydrate as compared with a low-fat diet in severe obesity. *N Engl J Med*. 2003;348(21):2074–2081.
26. Yancy WS, Jr., Olsen MK, Guyton JR, Bakst RP, Westman EC. A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial. *Ann Intern Med*. 2004;140(10):769–777.
27. Stern L, Iqbal N, Seshadri P, et al. The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial. *Ann Intern Med*. 2004;140(10):778–785.
28. Roberts SB. High-glycemic index foods, hunger, and obesity: is there a connection? *Nutr Rev*. 2000;58(6):163–169.
29. Jenkins DJ, Wolever TM, Taylor RH, et al. Glycemic index of foods: a physiological basis for carbohydrate exchange. *Am J Clin Nutr*. 1981;34(3):362–366.
30. Foster-Powell K, Holt SH, Brand-Miller JC. International table of glycemic index and glycemic load values: 2002. *Am J Clin Nutr*. 2002;76(1):5–56.
31. Brynes AE, Mark Edwards C, Ghatei MA, et al. A randomised four-intervention crossover study investigating the effect of carbohydrates on daytime profiles of insulin, glucose, non-esterified fatty acids and triacylglycerols in middle-aged men. *Br J Nutr*. 2003;89(2):207–218.
32. Meckling KA, O'Sullivan C, Saari D. Comparison of a low-fat diet to a low-carbohydrate diet on weight loss, body composition, and risk factors for diabetes and cardiovascular disease in free-living, overweight men and women. *J Clin Endocrinol Metab*. 2004;89(6):2717–2723.
33. Sloth B, Krog-Mikkelsen I, Flint A, et al. No difference in body weight decrease between a low-glycemic-index and a high-glycemic-index diet but reduced LDL cholesterol after 10-wk ad libitum intake of the low-glycemic-index diet. *Am J Clin Nutr*. 2004;80(2):337–347.
34. Ebbeling CB, Leidig MM, Sinclair KB, Seger-Shipee LG, Feldman HA, Ludwig DS. Effects of an ad

- libitum low-glycemic load diet on cardiovascular disease risk factors in obese young adults. *Am J Clin Nutr.* 2005;81(5):976–982.
35. Pittas AG, Das SK, Hajduk CL, et al. A low-glycemic load diet facilitates greater weight loss in overweight adults with high insulin secretion but not in overweight adults with low insulin secretion in the CALERIE Trial. *Diabetes Care.* 2005;28(12):2939–2941.
 36. Wolever TM, Mehling C. Long-term effect of varying the source or amount of dietary carbohydrate on postprandial plasma glucose, insulin, triacylglycerol, and free fatty acid concentrations in subjects with impaired glucose tolerance. *Am J Clin Nutr.* 2003;77(3):612–621.
 37. Spieth LE, Harnish JD, Lenders CM, et al. A low-glycemic index diet in the treatment of pediatric obesity. *Arch Pediatr Adolesc Med.* 2000;154(9):947–951.
 38. Ebbeling CB, Leidig MM, Sinclair KB, Hangen JP, Ludwig DS. A reduced-glycemic load diet in the treatment of adolescent obesity. *Arch Pediatr Adolesc Med.* 2003;157(8):773–779.
 39. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. *Lancet.* 2005;365(9467):1333–1346.
 40. Swinburn BA, Nyomba BL, Saad MF, et al. Insulin resistance associated with lower rates of weight gain in Pima Indians. *J Clin Invest.* 1991;88(1):168–173.
 41. Valdez R, Mitchell BD, Haffner SM, et al. Predictors of weight change in a bi-ethnic population. The San Antonio Heart Study. *Int J Obes Relat Metab Disord.* 1994;18(2):85–91.
 42. Hoag S, Marshall JA, Jones RH, Hamman RF. High fasting insulin levels associated with lower rates of weight gain in persons with normal glucose tolerance: the San Luis Valley Diabetes Study. *Int J Obes Relat Metab Disord.* 1995;19(3):175–180.
 43. Schwartz MW, Boyko EJ, Kahn SE, Ravussin E, Bogardus C. Reduced insulin secretion: an independent predictor of body weight gain. *J Clin Endocrinol Metab.* 1995;80(5):1571–1576.
 44. Sigal RJ, El-Hashimy M, Martin BC, Soeldner JS, Krolewski AS, Warram JH. Acute postchallenge hyperinsulinemia predicts weight gain: a prospective study. *Diabetes.* 1997;46(6):1025–1029.
 45. Folsom AR, Vitelli LL, Lewis CE, Schreiner PJ, Watson RL, Wagenknecht LE. Is fasting insulin concentration inversely associated with rate of weight gain? Contrasting findings from the CARDIA and ARIC study cohorts. *Int J Obes Relat Metab Disord.* 1998;22(1):48–54.
 46. Wedick NM, Mayer-Davis EJ, Wingard DL, Addy CL, Barrett-Connor E. Insulin resistance precedes weight loss in adults without diabetes: the Rancho Bernardo Study. *Am J Epidemiol.* 2001;153(12):1199–1205.
 47. Howard BV, Adams-Campbell L, Allen C, et al. Insulin resistance and weight gain in postmenopausal women of diverse ethnic groups. *Int J Obes Relat Metab Disord.* 2004;28(8):1039–1047.
 48. Lazarus R, Sparrow D, Weiss S. Temporal relations between obesity and insulin: longitudinal data from the Normative Aging Study. *Am J Epidemiol.* 1998;147(2):173–179.
 49. Mayer-Davis EJ, Kirkner GJ, Karter AJ, Zaccaro DJ. Metabolic predictors of 5-year change in weight and waist circumference in a triethnic population: the insulin resistance atherosclerosis study. *Am J Epidemiol.* 2003;157(7):592–601.
 50. Zavaroni I, Zuccarelli A, Gasparini P, Massironi P, Barilli A, Reaven GM. Can weight gain in healthy, nonobese volunteers be predicted by differences in baseline plasma insulin concentration? *J Clin Endocrinol Metab.* 1998;83(10):3498–3500.
 51. Boyko EJ, Leonetti DL, Bergstrom RW, Newell-Morris L, Fujimoto WY. Low insulin secretion and high fasting insulin and C-peptide levels predict increased visceral adiposity. 5-year follow-up among initially nondiabetic Japanese-American men. *Diabetes.* 1996;45(8):1010–1015.
 52. Silver RJ, Mehta S, Soeldner JS, Martin BC, Warram JH, Goldfine AB. Acute insulin secretion as a predictor of weight gain in healthy humans. *Obes Res.* 2006;14(1):67–72.
 53. Lillioja S, Nyomba BL, Saad MF, et al. Exaggerated early insulin release and insulin resistance in a diabetes-prone population: a metabolic comparison of Pima Indians and Caucasians. *J Clin Endocrinol Metab.* 1991;73(4):866–876.
 54. McLaughlin T, Abbasi F, Carantoni M, Schaaf P, Reaven G. Differences in insulin resistance do not predict weight loss in response to hypocaloric diets in healthy obese women. *J Clin Endocrinol Metab.* 1999;84(2):578–581.
 55. Casimirri F, Pasquali R, Cesari MP, Melchionda N, Barbara L. Interrelationships between body weight, body fat distribution and insulin in obese women before and after hypocaloric feeding and weight loss. *Ann Nutr Metab.* 1989;33(2):79–87.
 56. Mosca CL, Marshall JA, Grunwald GK, Cornier MA, Baxter J. Insulin resistance as a modifier of the relationship between dietary fat intake and weight gain. *Int J Obes Relat Metab Disord.* 2004;28(6):803–812.
 57. Baba NH, Sawaya S, Torbay N, Habbal Z, Azar S, Hashim SA. High protein vs high carbohydrate hypoenergetic diet for the treatment of obese hyperinsulinemic subjects. *Int J Obes Relat Metab Disord.* 1999;23(11):1202–1206.
 58. Cornier MA, Donahoo WT, Pereira R, et al. Insulin sensitivity determines the effectiveness of dietary macronutrient composition on weight loss in obese women. *Obes Res.* 2005;13(4):703–709.
 59. Gould AJ, Williams DE, Byrne CD, Hales CN, Wareham NJ. Prospective cohort study of the relationship of markers of insulin resistance and secretion with weight gain and changes in regional adiposity. *Int J Obes Relat Metab Disord.* 1999;23(12):1256–1261.
 60. Alemzadeh R, Langley G, Upchurch L, Smith P, Slonim AE. Beneficial effect of diazoxide in obese hyperinsulinemic adults. *J Clin Endocrinol Metab.* 1998;83(6):1911–1915.
 61. Velasquez-Mieyer PA, Cowan PA, Arheart KL, et al. Suppression of insulin secretion is associated with weight loss and altered macronutrient intake and preference in a subset of obese adults. *Int J Obes Relat Metab Disord.* 2003;27(2):219–226.
 62. Brand-Miller JC, Thomas M, Swan V, Ahmad ZI,

- Petocz P, Colagiuri S. Physiological validation of the concept of glycemic load in lean young adults. *J Nutr.* 2003;133(9):2728–2732.
63. Pawlak DB, Bryson JM, Denyer GS, Brand-Miller JC. High glycemic index starch promotes hypersecretion of insulin and higher body fat in rats without affecting insulin sensitivity. *J Nutr.* 2001;131(1):99–104.
 64. Pawlak DB, Kushner JA, Ludwig DS. Effects of dietary glycaemic index on adiposity, glucose homeostasis, and plasma lipids in animals. *Lancet.* 2004;364(9436):778–785.
 65. Wolever TM, Mehling C. High-carbohydrate-low-glycaemic index dietary advice improves glucose disposition index in subjects with impaired glucose tolerance. *Br J Nutr.* 2002;87(5):477–487.
 66. Poppitt SD, Keogh GF, Prentice AM, et al. Long-term effects of ad libitum low-fat, high-carbohydrate diets on body weight and serum lipids in overweight subjects with metabolic syndrome. *Am J Clin Nutr.* 2002;75(1):11–20.
 67. Bouche C, Rizkalla SW, Luo J, et al. Five-week, low-glycemic index diet decreases total fat mass and improves plasma lipid profile in moderately overweight nondiabetic men. *Diabetes Care.* 2002;25(5):822–828.
 68. Neel JV. Diabetes mellitus: a “thrifty” genotype rendered detrimental by “progress”? *Am J Hum Genet.* 1962;14:353–362.
 69. Hodge AM, Dowse GK, Alberti KG, Tuomilehto J, Gareeboo H, Zimmet PZ. Relationship of insulin resistance to weight gain in nondiabetic Asian Indian, Creole, and Chinese Mauritians. Mauritius Non-communicable Disease Study Group. *Metabolism.* 1996;45(5):627–633.
 70. Odeleye OE, de Courten M, Pettitt DJ, Ravussin E. Fasting hyperinsulinemia is a predictor of increased body weight gain and obesity in Pima Indian children. *Diabetes.* 1997;46(8):1341–1345.
 71. Dizon AM, Kowalyk S, Hoogwerf BJ. Neuroglycopenic and other symptoms in patients with insulinomas. *Am J Med.* 1999;106(3):307–310.
 72. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet.* 1998;352(9131):837–853.
 73. Sinha A, Formica C, Tsalamandris C, et al. Effects of insulin on body composition in patients with insulin-dependent and non-insulin-dependent diabetes. *Diabet Med.* 1996;13(1):40–46.
 74. Mayer J. Regulation of energy intake and body weight, the glucostatic theory and the lipostatic hypothesis. *Ann N Y Acad. Sci.* 1955;63:15–43.
 75. van Itallie TB. The glucostatic theory 1953–1988: roots and branches. *Int J Obes.* 1990;14(suppl 3):1–10.
 76. Pittas AG, Hariharan R, Stark PC, Hajduk CL, Greenberg AS, Roberts SB. Interstitial glucose level is a significant predictor of energy intake in free-living women with healthy body weight. *J Nutr.* 2005;135(5):1070–1074.
 77. Campfield LA, Smith FJ. Transient declines in blood glucose signal meal initiation. *Int J Obes.* 1990;14(suppl 3):15–31.
 78. Melanson KJ, Westerterp-Plantenga MS, Saris WH, Smith FJ, Campfield LA. Blood glucose patterns and appetite in time-blinded humans: carbohydrate versus fat. *Am J Physiol.* 1999;277(2 part 2):R337–R345.
 79. de Graaf C, Blom WA, Smeets PA, Stafleu A, Hendriks HF. Biomarkers of satiation and satiety. *Am J Clin Nutr.* 2004;79(6):946–961.
 80. Bray GA. Integration of energy intake and expenditure in animals and man: the autonomic and adrenal hypothesis. *Clin Endocrinol Metab.* 1984;13(3):521–546.
 81. Rodin J, Wack J, Ferrannini E, DeFronzo RA. Effect of insulin and glucose on feeding behavior. *Metabolism.* 1985;34(9):826–831.
 82. Inoue S, Bray GA. The effects of subdiaphragmatic vagotomy in rats with ventromedial hypothalamic obesity. *Endocrinology.* 1977;100(1):108–114.
 83. Tokunaga K, Fukushima M, Kemnitz JW, Bray GA. Effect of vagotomy on serum insulin in rats with paraventricular or ventromedial hypothalamic lesions. *Endocrinology.* 1986;119(4):1708–1711.
 84. Penicaud L, Kinebanyan MF, Ferre P, et al. Development of VMH obesity: in vivo insulin secretion and tissue insulin sensitivity. *Am J Physiol.* 1989;257(2 part 1):E255–E260.
 85. Brandes JS. Insulin induced overeating in the rat. *Physiol Behav.* 1977;18(6):1095–1102.
 86. Bruning JC, Gautam D, Burks DJ, et al. Role of brain insulin receptor in control of body weight and reproduction. *Science.* 2000;289(5487):2122–2125.
 87. Woods SC, Porte D, Jr., Bobbioni E, et al. Insulin: its relationship to the central nervous system and to the control of food intake and body weight. *Am J Clin Nutr.* 1985;42(suppl 5):1063–1071.
 88. Eckel RH. Insulin resistance: an adaptation for weight maintenance. *Lancet.* 1992;340(8833):1452–1453.
 89. Foster LA, Ames NK, Emery RS. Food intake and serum insulin responses to intraventricular infusions of insulin and IGF-I. *Physiol Behav.* 1991;50(4):745–749.
 90. Woods SC, Benoit SC, Clegg DJ, Seeley RJ. Clinical endocrinology and metabolism. Regulation of energy homeostasis by peripheral signals. *Best Pract Res Clin Endocrinol Metab.* 2004;18(4):497–515.
 91. Schwartz MW, Figlewicz DP, Baskin DG, Woods SC, Porte D Jr. Insulin in the brain: a hormonal regulator of energy balance. *Endocr Rev.* 1992;13(3):387–414.
 92. Ludwig DS, Majzoub JA, Al-Zahrani A, Dallal GE, Blanco I, Roberts SB. High glycemic index foods, overeating, and obesity. *Pediatrics.* 1999;103(3):E26.
 93. Yost TJ, Jensen DR, Eckel RH. Weight regain following sustained weight reduction is predicted by relative insulin sensitivity. *Obes Res.* 1995;3(6):583–587.
 94. Bergman RN, Prager R, Volund A, Olefsky JM. Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. *J Clin Invest.* 1987;79(3):790–800.